- Oops!Something went wrong.Please try again later.
As of late, it has definitely been a great time to be an investor in Adaptimmune Therapeutics plc ADAP. The stock has moved higher by more than 100% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path.
We certainly think that this might be the case, particularly if you consider ADAP’s recent earnings estimate revision activity. From this look, the company’s future is quite favorable; as ADAP has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn’t the top for the in-focus company. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Adaptimmune Therapeutics PLC (ADAP) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research